EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Jeng Shiuan Tsai
Meta Tag
Speaker Jeng Shiuan Tsai
Topic Metastatic NSCLC: Cytotoxic Therapy
treatment outcomes
second-line chemotherapy
EGFR mutation status
progression-free survival
overall survival
EGFR mutations
chemotherapy response
uncommon EGFR mutations
metastatic NSCLC
Powered By